Online citations, reference lists, and bibliographies.
← Back to Search

Effects Of Combined Therapies On The Survival Of Pleural Mesothelioma Patients Treated In Brescia, 1982–2006

P. Barbieri, A. Marinaccio, P. Ferrante, A. Scarselli, V. Pinelli, Gianfranco Tassi
Published 2012 ·

Cite This
Download PDF
Analyze on Scholarcy
Aims and background During the 1990's, the traditional unimodal treatments (surgery, radiotherapy, chemotherapy, immunotherapy) for malignant pleural mesothelioma started to be combined in bimodal or multimodal strategies. However, recent population-based analyses of the survival of patients with malignant pleural mesothelioma indicate that even these treatments have not led to significant improvements in prognosis, which remains very poor. The present study assessed the survival of patients given combined treatments and multimodal therapies in a specialized hospital department. Methods The study population comprised 530 patients diagnosed with malignant pleural mesothelioma from 1982 to 2006: 343 of them were residents in the province of Brescia (Lombardy, Northern Italy) and 187 were residents outside the province, with a follow-up to 31 December 2009. Kaplan-Meier survival analyses and Cox proportional risks model were used to test sex, age at diagnosis, histological type and treatments, as prognostic factors. Results The estimated median survival for the whole group of patients was 317 days (257 for residents and 398 for non-residents), and respectively 310 and 340 days in the groups diagnosed in the periods 1982–2000 and 2001–2006. Multivariate analysis confirmed that the prognosis was better for younger patients and cases of epithelioid type malignant pleural mesothelioma, whereas for patients receiving any single treatment the prognosis was not significantly better than for those given palliative care alone. However, patients receiving combined treatments or the multimodality approach had significantly longer median survival and the relative risk of death was respectively 0.57 and 0.61 compared to untreated patients (or those only given symptomatic therapy). Conclusions This is the first study in Italy to assess the effectiveness of different treatment approaches in a significant number of patients treated in one hospital. Further studies are needed to confirm the improvement in prognosis – even if modest – on larger numbers of patients and taking into account the different stages of the disease.
This paper references
A pilot Phase II study of cisplatin, doxorubicin, and vindesine for the treatment of malignant pleural mesothelioma
T Nakano (1993)
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)
Analisi della sopravvivenza dei mesoteliomi maligni trattati a Brescia dal
PG Barbieri (1982)
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988–2000: a population-based study
G. Gorini (2005)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Analysis of survival of mesothelioma cases in the Italian register (ReNaM).
A. Marinaccio (2003)
Survival after malignant mesothelioma . A population - base study in Italy
C Magnani (2002)
Prognostic factors of malignant mesothelioma of the pleura
V. de Pangher Manzini (1993)
Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma
C. Boutin (1994)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Survival after Pleural Malignant Mesothelioma a Population-based Study in Italy
C. Magnani (2002)
Well-differentiated Papillary Mesothelioma of the Pleura: A Series of 24 Cases
F. Galateau-Sallé (2004)
Linee guida per la rilevazione e la definizione dei casi di mesotelioma maligno e la trasmissione delle informazioni all'Ispesl da parte dei Centri Operativi Regionali. seconda edizione
It Istituto Superiore di Sanit (2004)
Predictions of mortality from pleural mesothelioma in Italy: A model based on asbestos consumption figures supports results from age‐period‐cohort models
A. Marinaccio (2005)
Estimation of the past and future burden of mortality from mesothelioma in France.
A. G. Ilg (1998)
E. Kaplan (1958)
Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma
C. Pinto (2011)
[Trends in mortality from primary pleural tumor and incidence of pleural mesothelioma in Italy: a particularly serious situation].
E. Merler (1999)
Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy.
Antonio Procopio (1998)
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
Survival analysis for mesothelioma cases in the Italian register ( Re Na M )
A Marinaccio (2003)
Analisi della sopravvivenza dei mesoteliomi maligni trattati a Brescia dal 1982 al 2000
PG Barbieri (2004)
Regression Models and Life-Tables

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar